Our top pick for
Building a portfolio
Bellicum Pharmaceuticals, Inc is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the NASDAQ and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 16 staff and has a trailing 12-month revenue of around USD$500,000.
|52-week range||USD$2.62 - USD$9.56|
|50-day moving average||USD$4.2806|
|200-day moving average||USD$4.4134|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.314|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-38,552,000|
|Return on assets TTM||-43.11%|
|Return on equity TTM||-143.13%|
|Market capitalisation||USD$29 million|
TTM: trailing 12 months
There are currently 862,982 Bellicum Pharmaceuticals shares held short by investors – that's known as Bellicum Pharmaceuticals's "short interest". This figure is 25.2% up from 689,053 last month.
There are a few different ways that this level of interest in shorting Bellicum Pharmaceuticals shares can be evaluated.
Bellicum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Bellicum Pharmaceuticals shares currently shorted divided by the average quantity of Bellicum Pharmaceuticals shares traded daily (recently around 501733.72093023). Bellicum Pharmaceuticals's SIR currently stands at 1.72. In other words for every 100,000 Bellicum Pharmaceuticals shares traded daily on the market, roughly 1720 shares are currently held short.
However Bellicum Pharmaceuticals's short interest can also be evaluated against the total number of Bellicum Pharmaceuticals shares, or, against the total number of tradable Bellicum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellicum Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Bellicum Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1418% of the tradable shares (for every 100,000 tradable Bellicum Pharmaceuticals shares, roughly 142 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellicum Pharmaceuticals.
Find out more about how you can short Bellicum Pharmaceuticals stock.
We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.
Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 5 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.
Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $2.62 up to $9.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.7468. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.